NR3C2 and cardiovascular disorder: In the both cohorts along with increased C2HEST score, we observed an increasing prevalence drug commonly used in cardiovascular disorders such as angiotensin-converting-enzyme inhibitors (ACEI), mineralocorticoid receptor antagonists (MRA), b-blockers, calcium channel blockers, diuretics, statins, vitamin K antagonists (VKA), novel oral anticoagulants (NOAC), acetylsalicylic acid, P2Y12 inhibitor, metformin, and insulin.